APTOCROM Decides to Acquire 50.3 Billion Won Convertible Bond from Affiliate Aprogen Biologics with Sharp Conversion Price Cut, Posing Severe Dilution Risk

APTOCROM has decided to acquire the 20th series unsecured private convertible bond worth 50.3 billion won issued by its affiliate Aprogen Biologics.
The acquisition amount will be paid by offsetting existing loan receivables, with the stated purpose of improving financial structure.
The conversion price was sharply lowered from the initial preliminary price of 3,778 won to 2,353 won, representing a 37.7% reduction, which would result in approximately 21.38 million new shares upon full conversion, equivalent to 141% of current outstanding shares.
The convertible bond carries a 2% coupon and 4% yield to maturity, with a put option exercisable 18 months after issuance.
The transaction lacks transparency due to related-party nature and the use of funds is merely defensive, with no clear growth or value creation strategy.
The current stock price of 1,790 won is below the conversion price of 2,353 won, reducing immediate conversion incentive, but any price recovery would lead to massive dilution.
[AI Summary]APTOCROM's acquisition of an affiliate's convertible bond with a severely lowered conversion price implies a potential dilution of over 140% of outstanding shares, posing a high risk to existing shareholders. The defensive capital allocation and related-party governance concerns further undermine shareholder value.